Meril Life Sciences receives European certification for stents

Polymer stents have also got DCGI, CE marketing approvals

August 16, 2019 12:37 am | Updated 12:37 am IST - Vapi

Vapi-based Meril Life Sciences has become the first Indian company to receive European Conformity (CE) marking for its 100 micron bioresorbable scaffold (BRS), or dissolvable polymer stents. The company will soon make it available across various countries later this year.

The product MeRes100, a next generation thin-strut BRS, has been designed and manufactured using technology developed by Meril Life Sciences at its facility in Vapi, Gujarat. The product, backed by research and clinical trial data, has received both Drug Controller General of India and CE marketing approvals.

Sanjeev Bhatt, vice president-corporate strategy, Meril Life Sciences, told The Hindu that metallic drug eluting stents (DES), which are in use as a primary intervention for treating coronary artery disease and associated lesions or blockages due to fat deposition and plaque formation, have a metallic platform with drug coating. “The role of a DES is to provide temporary scaffolding to the blockage or lesion site and also to deliver a drug to facilitate healing. After healing is complete, the metallic stent remains in the body as a permanent implant. Such metallic DES are associated with incremental risk of clinical or adverse events,” Mr. Bhatt said.

Meril said its 100 micron BRS was a result of intensive research and development efforts by 150 scientists, chemists, engineers and researchers at its research facilities in Vapi over five years, which have got it multiple regulatory approvals and over seven patents.

Data collated by Meril shows that on an average, 2-3% of patients with metallic DES implants may require a repeat intervention year on year. “MeRes100 was designed as a solution to bridge this gap between the temporary treatment horizon for opening a blockage and the undesirably permanent nature of a metallic DES implant,” Mr. Bhatt said.

Through MeRes-1, the first in-human study conducted in India and MeRes-1 Extend, conducted in Brazil, Europe and Asia, MeRes100 BRS has shown long-term safety and sustained efficacy for patients with coronary artery disease. The proprietary hybrid-cell design of MeRes100 ensures better deliverability. The scaffold strut thickness is 100 microns, which leads to faster healing, resulting in lower risk of scaffold thrombosis, Mr. Bhatt said. Both trials had also validated this benefit, he said.

Dr. Praveen Chandra, chairman of interventional cardiology at Medanta – The Medicity, Gurgaon, who was co-principal investigator of MeRes-1 Study observed that the cumulative major adverse cardiac event rate, which includes cardiac death or heart attack, is better at three years for MeRes100 as compared to previous generation BRS technology.

“First generation bioresorbable scaffolds have not shown the most favourable results in long-term horizons. The next generation bioresorbable scaffold with reduced strut thickness, improved profile for better deliverability, faster degradation and possibly lower scaffold thrombosis is a revolutionary advance in interventional cardiology,” principal investigator for the MeRes-1 trial Dr. Ashok Seth, chairman of Fortis Escorts Heart Institute, New Delhi, said.

(The writer was in Vapi at the invitation of Meril Life Sciences)

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.